Summit Therapeutics Inc [NASDAQ: SMMT] gained 7.05% on the last trading session, reaching $20.5 price per share at the time.
Summit Therapeutics Inc represents 742.81 million in outstanding shares, while the company has a total market value of $15.22 billion with the latest information. SMMT stock price has been found in the range of $19.22 to $20.55.
If compared to the average trading volume of 4.05M shares, SMMT reached a trading volume of 4683985 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Summit Therapeutics Inc [SMMT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SMMT shares is $32.71 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SMMT stock is a recommendation set at 1.62. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Summit Therapeutics Inc shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on September 17, 2025. While these analysts kept the previous recommendation, Guggenheim raised their target price to Buy. The new note on the price target was released on September 04, 2025, representing the official price target for Summit Therapeutics Inc stock. Previously, the target price had yet another raise to $21, while Piper Sandler analysts kept a Neutral rating on SMMT stock.
The Price to Book ratio for the last quarter was 58.69, with the Price to Cash per share for the same quarter was set at 0.40.
Trading performance analysis for SMMT stock
Summit Therapeutics Inc [SMMT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.32. With this latest performance, SMMT shares dropped by -21.96% in over the last four-week period, additionally plugging by 1.28% over the last 6 months – not to mention a rise of 14.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SMMT stock in for the last two-week period is set at 45.39, with the RSI for the last a single of trading hit 1.39, and the three-weeks RSI is set at 1.57 for Summit Therapeutics Inc [SMMT]. The present Moving Average for the last 50 days of trading for this stock 24.59, while it was recorded at 19.37 for the last single week of trading, and 22.08 for the last 200 days.
Summit Therapeutics Inc (SMMT) Capital Structure & Debt Analysis
According to recent financial data for Summit Therapeutics Inc. ( SMMT), the Return on Equity (ROE) stands at -328.30%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -224.08%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Summit Therapeutics Inc’s Return on Invested Capital (ROIC) is -284.90%, showcasing its effectiveness in deploying capital for earnings.
Summit Therapeutics Inc (SMMT) Efficiency & Liquidity Metrics
Based on Summit Therapeutics Inc’s (SMMT) latest financial statements, the Debt-to-Equity Ratio is 0.02%, indicating its reliance on debt financing relative to shareholder equity.
Summit Therapeutics Inc (SMMT) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Summit Therapeutics Inc. (SMMT) effectively leverages its workforce, generating an average of -$4692327.04 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.13% and a Quick Ratio of 5.13%, indicating strong ability to cover short-term liabilities.
Summit Therapeutics Inc [SMMT]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Summit Therapeutics Inc posted -0.06/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SMMT.
An analysis of Institutional ownership at Summit Therapeutics Inc [SMMT]
There are presently around $13.55%, or 86.57%% of SMMT stock, in the hands of institutional investors. The top three institutional holders of SMMT stocks are: BAKER BROS. ADVISORS LP with ownership of 23.22 million shares, which is approximately 3.2804%. VANGUARD GROUP INC, holding 8.82 million shares of the stock with an approximate value of $$68.78 million in SMMT stocks shares; and VANGUARD GROUP INC, currently with $$61.61 million in SMMT stock with ownership which is approximately 1.1158%.
